Date 22/05/2022

To,

The Editor
World journal of hepatology

Subject: Revised manuscript Number ID: 05266965, Title: Sexual Dysfunctions and their treatment in Liver Diseases, Manuscript Type: Opinion Review

Dear Sir/Madam,

We thank you for providing us with an opportunity to revise our previously submitted invited review Sexual Dysfunctions and their treatment in Liver Diseases. I am enclosing the revised version of the manuscript entitled “Sexual Dysfunctions and their treatment in Liver Diseases”. We have addressed all the queries from the reviewers and have included these replies in the letter. We have revised the manuscript and the changes in the manuscript are highlighted with red.

We do hope you would find the revised version of the review article most updated and balanced, and worthy of publication in ‘World Journal of Hepatology’.

With kind regards,

Rakesh Kumar Jagdish M.D., D.M.

Answer to reviewers:

Answer to reviewer1: (05533112)

Thank you for the constructive comments to help us improve our manuscript. I have incorporated your suggestions and have included the suggestions, in the revised version.

Global epidemiological data on sexual dysfunction /erectile dysfunction is tabulated in table 1, and described on page 3, under Incidence and Prevalence of SD heading.

The interplay between SD and CLD is summarised in figure 1, and there’re are multifactorial causation of SD in CLD, like hormonal disturbances and other non-hormonal causes discussed.
Newer prospects are added especially concept of sexual frailty, and future prospects in this aspect.

Multiple other future prospects added at the relevant points in discussion.

**Answer to reviewer 2: (02860797)**

I am thankful and appreciate the comments of the reviewer for this valuable advice.

Studies on Live donor liver transplant (LDLT), and SD are few and with conflicting results, therefore large RCT are required.

Efficacy of PDE5 inhibitors have been discussed as shown in a recent trial RCT on Tadalafil from our group.

Figure 3: shows Clinical approach to treatment and Figure 4: shows treatment of SD in liver diseases.

Quality of life in SD is disturbed in CLD as well as non CLD, are discussed in page no 4, under headings of Risk factors contributing for ED in Liver Diseases in both genders, references 11-13.

I again thank the reviewer for valuable suggestions. Accordingly, rearrangement of the article done.

**Answer to reviewer 3: (03232194)**

I am greatly thankful to the reviewer for the comment and as advised, this section has been added in the revised manuscript.

Prospective research contents are added at multiple points in discussion. Table 21 number has changed to table 1.